N@N

SANUWAVE Health Reports First Quarter Financial Results

_{//health-fitness.news-articles.net/content/2011/ .. lth-reports-first-quarter-financial-results.html}
^{Published in Health and Fitness on Monday, May 16th 2011 at 5:05 GMT by Market Wire}  

ALPHARETTA, Ga.--([ BUSINESS WIRE ])--SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response-activating devices in regenerative medicine, today reported financial results for the three months ended March 31, 2011.

"During the first quarter of 2011, we made significant progress in a number of areas important to building a sustainable growth company"

aDuring the first quarter of 2011, we made significant progress in a number of areas important to building a sustainable growth company,a said Christopher M. Cashman, President and CEO of SANUWAVE. aIn addition to advancing our modular Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for dermaPACE^® to treat diabetic foot ulcers (DFU), we continued to strengthen our balance sheet by raising more than $3.9 million through investors exercising options to purchase common stock and warrants. In addition, after quarter end, in April 2011 we raised an additional $9.1 million through a private placement of our common stock to high quality institutional investors and other accredited investors and exchanged $4.4 million of our senior debt into common stock and warrants.a

aWe continue to publish and present positive data in support of the clinical utility and safety of dermaPACE for the DFU indication. The robust results from our Phase III clinical trial showed that patients treated with dermaPACE were twice as likely to achieve wound closure of at least 90% within 12 weeks of their initial dermaPACE treatment versus patients randomized to receive sham control, suggesting the potential of dermaPACEto be a novel, non-pharmacologic and noninvasive advanced wound healing modality. We look forward to submitting the final PMA module in the second quarter and, pending a favorable response, to offering medical professionals and their patients a novel solution for these debilitating foot ulcers, with both clinical and economic benefit.a

Business highlights from the first quarter include the following:

• Submitted the second of three PMA modules to the FDA for dermaPACE for the treatment of DFU.
• Reported the publication of data from a study conducted in Taiwan in Diabetes Research and Clinical Practice, which showed dermaPACE demonstrated significantly improved healing compared with hyperbaric oxygen treatments (HBOT) with 85% fewer treatments and 97% less treatment time than HBOT.
• Raised $3.9 million from the exercise of options that were issued as part of the sale of units to accredited investors during 2010.
• Granted a U.S. patent that provides the Company with the rights for devices that use piezoelectric fibers to produce acoustic energy in the shock wave spectrum. Piezoelectric fiber technology creates a small, easily targeted focal volume of energy that can be precisely pointed in the targeted tissue while minimizing exposure to surrounding tissue.

In addition, subsequent to quarter end in April 2011, the Company raised $9.1 million in a private placement and exchanged $4.4 million in senior notes for common stock and warrants.

Mr. Cashman added, aAs we make plans for product commercialization, the foundation of our marketing efforts will be supported by the ongoing clinical validation of dermaPACE in wound healing. Toward that end, podium and poster presentations of our positive clinical data demonstrating dermaPACEa™s ability to safely and effectively treat diabetic foot ulcers will be delivered at several upcoming medical congresses, and we expect to submit these data for publication in a peer-reviewed medical journal.a

First Quarter Financial Results

Revenues for the first quarter of 2011 were $252,000, compared with $143,000 for the first quarter of 2010. The increase in revenues for 2011, as compared to the same period in 2010, are primarily from sales in Europe of our new product, orthoPACE^®, for orthopedics, sports medicine and trauma indications, which was launched in July 2010.

Research and development expenses during the first quarter of 2011 were $749,000, compared with $1.1 million for 2010 first quarter. The decrease is due to lower clinical trial costs associated with the dermaPACE DFU clinical trial, which completed enrollment and patient follow-up in 2010.

General and administrative expenses during the first quarter of 2011 were $1.4 million, including non-cash stock-based compensation costs of $152,000, compared with $1.6 million, including non-cash stock-based compensation costs of $483,000, for the same period in 2010. The decrease in non-cash stock-based compensation costs in 2011, as compared to the same period in 2010, was primarily due to restricted stock granted in 2009 that became fully vested and expensed as of January 1, 2011. Excluding non-cash stock-based compensation costs, general and administrative expenses for the first quarter of 2011 increased by $115,000 over the prior yeara™s first quarter mainly due to higher legal and public company costs as a result of capital raising activities.

The net loss for the first quarter of 2011 was $2.2 million or $0.14 per share, compared with a net loss of $3.0 million or $0.24 per share for the first quarter of 2010.

As of March 31, 2011, the Company had cash and cash equivalents of $2.3 million, compared with $417,000 as of December 31, 2010. During the first quarter of 2011, the Company raised $3.9 million from the exercise of options that were issued as part of the sale of units to accredited investors during 2010. Net cash used by operations for the first quarter of 2011 was $2.0 million, compared with $1.7 million for the first quarter of 2010, primarily due to a reduction in accounts payable in 2011 as compared to 2010.

After quarter end, in April 2011 the Company sold securities to investors in a private placement for gross proceeds of approximately $9.1 million. Net proceeds received by the Company were $8.5 million, net of offering costs of $0.6 million. The Company intends to use the proceeds of this private placement for general working capital purposes. The investors in the financing included high-quality healthcare-focused institutional funds. Under the terms of the offering, the Company sold an aggregate of approximately 2.8 million shares of common stock at a price of $3.25 per share.The purchasers also received warrants to purchase up to an aggregate of approximately 2.8 million shares of common stock at an exercise price of $4.00 per share. The warrants will expire in five years. The Company filed a resale registration statement that covers the resale of the shares by the purchasers and the shares issuable upon exercise of the warrants with the Securities and Exchange Commission on May 10, 2011.

In addition, in April 2011, the Company and holders of the senior notes outstanding agreed to exchange the notes with a balance of principal and accrued interest of $4.4 million into 1,358,126 shares of common stock of the Company. The note holders also received warrants to purchase up to an aggregate of 679,064 shares of common stock at an exercise price of $4.00 per share. The warrants will expire in five years.

About PACE^®

PACE, defined as Pulsed Acoustic Cellular Expression, delivers high-energy acoustic pressure waves to produce compressive and tensile stresses on cells and tissue structures to promote angiogenic and positive inflammatory responses, and quickly initiate the healing cascade. This results in revascularization and microcirculatory improvement, including the production of angiogenic growth factors, enhanced new blood vessel formation (angiogenesis), and the subsequent regeneration of tissue such as skin, musculoskeletal and vascular structures. PACE treatment triggers the initiation of an accelerated inflammatory response that speeds wounds into proliferation phases of healing, and subsequently returns a chronic condition to an acute condition to help re-initiate the bodya™s own healing response.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. ([ www.sanuwave.com ]) is an emerging regenerative medicine company focused on the development and commercialization of non-invasive, biological response-activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVEa™s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the bodya™s normal healing processes and regeneration. SANUWAVE intends to apply its PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE, is CE marked for treatment of the skin and subcutaneous soft tissue and recently completed its highly positive pivotal Phase III, Investigational Device Exemption (IDE) trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron^® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron, Evotrona" and orthoPACE devices in Europe.

Forward-Looking Statements

This press release may contain aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companya™s ability to control.Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Companya™s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Companya™s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Companya™s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.